EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access

Risk of Obesity in Patients Treated with Clozapine or Olanzapine: A Simple, Clinically Useful Prediction Tool

Roberto Lozano, Carina Bona

Psychopharmacology Bulletin · 2026

DOI: 10.64719/pb.15423 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Psychopharmacology Bulletin, 2026. Verfasst von Roberto Lozano und 1 weiteren Autor:innen. Beteiligte Einrichtung: Lozano, PhD, PharmD., Department of Pharmacy, University Clinical Hospital "Lozano Blesa", Zaragoza, Spain. Hauptthemen laut MEDLINE: Olanzapine, Clozapine, Antipsychotic Agents, Obesity. Die Arbeit nennt 6 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Clozapine and olanzapine are associated with clinically relevant weight gain and metabolic risk.

Objective

To compare the risk of obesity (BMI ⩾ 30) between clozapine and olanzapine and to develop a parsimonious prediction model with performance and clinical-utility evaluation.

Methods

We fit a multivariable logistic regression on complete cases using index drug, daily dose, prolactin (PRL), cortisol, free thyroxine (FT4), and HDL. Discrimination (AUC), probability accuracy (Brier score), calibration (intercept/slope and deciles), and decision-curve analysis (DCA) were reported.

Results

In the classification cohort, obesity counts were equal for clozapine (9/19) and olanzapine (9/19). The model achieved strong internal discrimination (AUC 0.869) with good calibration (slope 1.00; intercept −0.00) and Brier 0.123. DCA indicated net benefit at practical thresholds (∼5–15%), supporting low-harm preventive actions.

Conclusions

Drug-related risk can be individualized with a lean model using routine variables. External validation and unit harmonization—especially for HDL—are recommended before broad deployment. Psychopharmacology Bulletin. 2026;56(1):71–81.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OlanzapineClozapineAntipsychotic AgentsObesityBenzodiazepinesHumansFemaleMaleAdultPrediction AlgorithmsLogistic ModelsMiddle AgedRisk FactorsBody Mass Index

Stichwörter der Autor:innen

body mass indexclozapineolanzapine

Substanzen

OlanzapineClozapineAntipsychotic AgentsBenzodiazepines

Autor:innen und Institutionen

  • Lozano, PhD, PharmD., Department of Pharmacy, University Clinical Hospital "Lozano Blesa", Zaragoza, Spain.
  • Bona, Unit for the Rational Use of Medicines, Aragon Health Service, Zaragoza, Spain.

Zitieren

APA

Lozano, R., & Bona, C. (2026). Risk of Obesity in Patients Treated with Clozapine or Olanzapine: A Simple, Clinically Useful Prediction Tool. Psychopharmacology Bulletin. https://doi.org/10.64719/pb.15423

Vancouver

Lozano R, Bona C. Risk of Obesity in Patients Treated with Clozapine or Olanzapine: A Simple, Clinically Useful Prediction Tool. Psychopharmacology Bulletin. 2026. doi:10.64719/pb.15423

BibTeX
@article{Lozano2026,
  author = {Lozano, Roberto and Bona, Carina},
  title = {Risk of Obesity in Patients Treated with Clozapine or Olanzapine: A Simple, Clinically Useful Prediction Tool},
  journal = {Psychopharmacology Bulletin},
  year = {2026},
  doi = {10.64719/pb.15423}
}
Kostenlos starten →